| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/27/2023 | 32.92% | UBS | $11 → $13 | Upgrades | Neutral → Buy |
| 09/20/2023 | 12.47% | UBS | $8 → $11 | Maintains | Neutral |
| 09/08/2023 | 32.92% | B of A Securities | $12 → $13 | Maintains | Buy |
| 07/06/2023 | -18.2% | UBS | $7 → $8 | Upgrades | Sell → Neutral |
| 05/25/2023 | 2.25% | Morgan Stanley | → $10 | Initiates Coverage On | → Equal-Weight |
| 05/18/2023 | — | Evercore ISI Group | Upgrades | In-Line → Outperform | |
| 05/11/2023 | 12.47% | B of A Securities | $13 → $11 | Maintains | Buy |
| 02/09/2023 | 43.15% | Barclays | $13 → $14 | Maintains | Overweight |
| 01/19/2023 | 22.7% | Jefferies | $10 → $12 | Downgrades | Buy → Hold |
| 11/23/2022 | -28.43% | Piper Sandler | $8 → $7 | Maintains | Underweight |
| 11/14/2022 | 2.25% | JP Morgan | $11 → $10 | Downgrades | Neutral → Underweight |
| 11/07/2022 | 2.25% | BMO Capital | $11 → $10 | Maintains | Market Perform |
| 10/21/2022 | 2.25% | Jefferies | → $10 | Assumes | → Buy |
| 08/05/2022 | 32.92% | B of A Securities | $10 → $13 | Upgrades | Neutral → Buy |
| 08/02/2022 | 2.25% | Goldman Sachs | $9 → $10 | Maintains | Neutral |
| 06/14/2022 | 2.25% | UBS | → $10 | Initiates Coverage On | → Neutral |
| 05/17/2022 | -7.98% | B of A Securities | → $9 | Upgrades | Underperform → Neutral |
| 05/12/2022 | -7.98% | Goldman Sachs | $10 → $9 | Maintains | Neutral |
| 05/04/2022 | -28.43% | Piper Sandler | $11 → $7 | Downgrades | Neutral → Underweight |
| 04/05/2022 | 32.92% | Barclays | $11 → $13 | Upgrades | Equal-Weight → Overweight |
| 02/18/2022 | 12.47% | Barclays | $13 → $11 | Maintains | Equal-Weight |
| 01/27/2022 | — | Argus Research | Downgrades | Buy → Hold | |
| 10/28/2021 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 07/29/2021 | 43.15% | Raymond James | $15 → $14 | Maintains | Outperform |
| 07/29/2021 | 12.47% | Wells Fargo | $12 → $11 | Maintains | Equal-Weight |
| 05/04/2021 | 12.47% | UBS | $15 → $11 | Downgrades | Buy → Neutral |
| 11/25/2020 | — | Oppenheimer | Initiates Coverage On | → Perform | |
| 11/06/2020 | 12.47% | BMO Capital | $13 → $11 | Maintains | Market Perform |
| 08/06/2020 | 32.92% | Barclays | → $13 | Upgrades | Underweight → Equal-Weight |
| 08/06/2020 | 43.15% | SVB Leerink | $13 → $14 | Maintains | Market Perform |
| 07/27/2020 | 22.7% | Goldman Sachs | → $12 | Initiates Coverage On | → Neutral |
| 06/01/2020 | 63.6% | SunTrust Robinson Humphrey | $11 → $16 | Upgrades | Hold → Buy |
| 05/11/2020 | 53.37% | UBS | $12 → $15 | Maintains | Buy |
| 05/08/2020 | 22.7% | SVB Leerink | $11 → $12 | Maintains | Market Perform |
| 05/08/2020 | -18.2% | B of A Securities | $7 → $8 | Reiterates | → Underperform |
| 04/15/2020 | -18.2% | Piper Sandler | $10 → $8 | Maintains | Neutral |
| 04/06/2020 | — | UBS | Upgrades | Neutral → Buy | |
| 04/02/2020 | -18.2% | Morgan Stanley | $13 → $8 | Maintains | Underweight |
| 03/23/2020 | -28.43% | B of A Securities | $11 → $7 | Maintains | Underperform |
| 03/05/2020 | 22.7% | Wells Fargo | $10 → $12 | Maintains | Equal-Weight |
| 02/18/2020 | 53.37% | Argus Research | $10 → $15 | Maintains | Buy |
| 02/14/2020 | 32.92% | Morgan Stanley | $8 → $13 | Maintains | Underweight |
| 02/13/2020 | 12.47% | B of A Securities | $8 → $11 | Maintains | Underperform |
| 02/13/2020 | 32.92% | SunTrust Robinson Humphrey | $9 → $13 | Maintains | Hold |
| 02/13/2020 | 63.6% | Oppenheimer | $12 → $16 | Maintains | Outperform |
| 02/12/2020 | 53.37% | Cantor Fitzgerald | $9 → $15 | Maintains | Neutral |
| 02/12/2020 | 32.92% | CFRA | $11 → $13 | Maintains | Hold |
| 01/22/2020 | 2.25% | Wells Fargo | $8 → $10 | Maintains | Equal-Weight |
| 11/12/2019 | — | JP Morgan | Upgrades | Underweight → Neutral | |
| 11/08/2019 | -28.43% | Piper Sandler | $6 → $7 | Maintains | Neutral |
| 10/17/2019 | — | Gabelli & Co. | Upgrades | Hold → Buy | |
| 09/30/2019 | -18.2% | Wells Fargo | $17 → $8 | Maintains | Market Perform |
| 09/12/2019 | — | Guggenheim | Initiates Coverage On | → Neutral | |
| 09/06/2019 | -28.43% | JP Morgan | $9 → $7 | Maintains | Underweight |
| 08/09/2019 | -7.98% | BMO Capital | $11 → $9 | Maintains | Market Perform |
| 07/15/2019 | -38.65% | Morgan Stanley | $16 → $6 | Downgrades | Equal-Weight → Underweight |
| 07/10/2019 | — | Credit Suisse | Assumes | → Neutral | |
| 06/11/2019 | -18.2% | Barclays | → $8 | Initiates Coverage On | → Underweight |
| 06/03/2019 | 22.7% | Oppenheimer | → $12 | Upgrades | Perform → Outperform |
| 05/30/2019 | -7.98% | B of A Securities | $19 → $9 | Downgrades | Buy → Underperform |
| 05/28/2019 | 22.7% | UBS | $22 → $12 | Downgrades | Buy → Neutral |
| 05/09/2019 | 73.82% | Wells Fargo | $18 → $17 | Maintains | Market Perform |
| 04/11/2019 | 135.17% | Citigroup | $27 → $23 | Maintains | Buy |
| 04/03/2019 | 84.05% | Wells Fargo | $20 → $18 | Maintains | Market Perform |
| 03/28/2019 | 84.05% | BMO Capital | → $18 | Initiates Coverage On | → Market Perform |
| 03/20/2019 | 73.82% | SunTrust Robinson Humphrey | → $17 | Initiates Coverage On | → Hold |
| 03/07/2019 | 124.95% | UBS | → $22 | Reinstates | → Buy |
| 03/06/2019 | 73.82% | Morgan Stanley | → $17 | Downgrades | Overweight → Equal-Weight |
| 02/14/2019 | 104.5% | Credit Suisse | $26 → $20 | Maintains | Neutral |
| 02/14/2019 | — | Raymond James | Upgrades | Market Perform → Outperform | |
| 01/23/2019 | 63.6% | Piper Sandler | $15 → $16 | Upgrades | Underweight → Neutral |
| 01/03/2019 | — | B of A Securities | Upgrades | Underperform → Buy |
What is the target price for Teva Pharmaceutical Indus (TEVA)?
The latest price target for Teva Pharmaceutical Indus (NYSE: TEVA) was reported by UBS on November 27, 2023. The analyst firm set a price target for $13.00 expecting TEVA to rise to within 12 months (a possible 32.92% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Teva Pharmaceutical Indus (TEVA)?
The latest analyst rating for Teva Pharmaceutical Indus (NYSE: TEVA) was provided by UBS, and Teva Pharmaceutical Indus upgraded their buy rating.
When is the next analyst rating going to be posted or updated for Teva Pharmaceutical Indus (TEVA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Teva Pharmaceutical Indus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Teva Pharmaceutical Indus was filed on November 27, 2023 so you should expect the next rating to be made available sometime around November 27, 2024.
Is the Analyst Rating Teva Pharmaceutical Indus (TEVA) correct?
While ratings are subjective and will change, the latest Teva Pharmaceutical Indus (TEVA) rating was a upgraded with a price target of $11.00 to $13.00. The current price Teva Pharmaceutical Indus (TEVA) is trading at is $9.78, which is out of the analyst's predicted range.